InMed Pharmaceuticals Inc (NASDAQ: INM)’s stock price has decreased by -4.59% compared to its previous closing price of $3.05. However, the company has seen a -15.90% decrease in its stock price over the last five trading sessions. newsfilecorp.com reported 2025-06-27 that Vancouver, British Columbia–(Newsfile Corp. – June 27, 2025) – InMed Pharmaceuticals Inc. (NASDAQ: INM) (“InMed” or the “Company”), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced the closing of its previously announced private placement priced at-the-market under Nasdaq rules for the issuance and sale of 1,952,363 of its common shares (or pre-funded warrants in lieu thereof) and short-term preferred investment options to purchase up to an aggregate of 1,952,363 common shares, at a purchase price of $2.561 per share (or pre-funded warrant in lieu thereof) and associated short-term preferred investment option. The short-term preferred investment option issued in the offering is exercisable immediately upon issuance at an exercise price of $2.436 per share and will expire eighteen months from the effective date of the Resale Registration Statement (as defined below).
Is It Worth Investing in InMed Pharmaceuticals Inc (NASDAQ: INM) Right Now?
Moreover, the 36-month beta value for INM is 0.48. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy”, 0 as “overweight”, 1 as “hold”, and 0 as “sell”.
The public float for INM is 1.20M and currently, short sellers hold a 2.74% of that float. On July 04, 2025, INM’s average trading volume was 3.17M shares.
INM’s Market Performance
INM’s stock has seen a -15.90% decrease for the week, with a -12.35% drop in the past month and a 40.24% gain in the past quarter. The volatility ratio for the week is 6.06%, and the volatility levels for the past 30 days are at 12.58% for InMed Pharmaceuticals Inc The simple moving average for the past 20 days is -0.34% for INM’s stock, with a -21.85% simple moving average for the past 200 days.
INM Trading at 1.06% from the 50-Day Moving Average
After a stumble in the market that brought INM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -81.46% of loss for the given period.
Volatility was left at 12.58%, however, over the last 30 days, the volatility rate increased by 6.06%, as shares sank -2.35% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -0.68% lower at present.
During the last 5 trading sessions, INM fell by -15.90%, which changed the moving average for the period of 200-days by -44.34% in comparison to the 20-day moving average, which settled at $2.92. In addition, InMed Pharmaceuticals Inc saw -42.17% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at INM starting from MANCINI ALEXANDRA DIANE JANET, who sold 240 shares at the price of $0.18 back on Jul 31 ’24. After this action, MANCINI ALEXANDRA DIANE JANET now owns 0 shares of InMed Pharmaceuticals Inc, valued at $42 using the latest closing price.
N/A, the N/A of InMed Pharmaceuticals Inc, N/A N/A shares at N/A during a trade that took place back on N/A, which means that N/A is holding N/A shares at N/A based on the most recent closing price.
Stock Fundamentals for INM
Current profitability levels for the company are sitting at:
- -1.77% for the present operating margin
- -2.67% for the gross margin
The net margin for InMed Pharmaceuticals Inc stands at -2.68%. The total capital return value is set at -0.57%. Equity return is now at value -91.71%, with -73.43% for asset returns.
Based on InMed Pharmaceuticals Inc (INM), the company’s capital structure generated 0.06 points at debt to capital in total, while cash flow to debt ratio is standing at -18.63.
Currently, EBITDA for the company is -7.06 million with net debt to EBITDA at 1.04. When we switch over and look at the enterprise to sales, we see a ratio of -1.79. The receivables turnover for the company is 6.46for trailing twelve months and the total asset turnover is 0.26. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.49.
Conclusion
To wrap up, the performance of InMed Pharmaceuticals Inc (INM) has been bad in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
